GSK Gets 2nd Chance To Argue Preemption In Zofran MDL
A Massachusetts federal judge on Wednesday said GlaxoSmithKline will get another chance to argue that claims its anti-nausea drug Zofran caused birth defects are federally preempted, adding he will seek guidance...To view the full article, register now.
Already a subscriber? Click here to view full article